Expert Opinion on Therapeutic Patents

Papers
(The H4-Index of Expert Opinion on Therapeutic Patents is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Malaria transmission blocking compounds: a patent review37
Recent developments of agents targeting Vibrio cholerae : patents and literature data37
FAK inhibitors in cancer, a patent review – an update on progress37
The role of patent analysis in target selection36
Update on mGlu4 modulator patents: 2017 to present34
Traf2- and Nck-interacting kinase inhibitors: a patent review (2008–2024)33
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)33
RORγt inhibitors in clinical development for the treatment of autoimmune diseases: challenges and opportunities32
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)29
Caspase inhibitors: a review on recently patented compounds (2016–2023)27
P2Y 12 R antagonists in antithrombotic therapy: a patent and literature review (2019–present)24
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)24
A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present24
Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review24
A patent review of hepatitis B virus core protein allosteric modulators (2019-present)22
P2X receptor antagonists and their potential as therapeutics: a patent review (2010–2021)22
An updated patent review of AKT inhibitors (2020 – present)22
Patent review of cannabinoid receptor type 2 (CB 2 R) modulators (2016-present)22
A patent review of MAPK inhibitors (2018 – present)21
Inhibition of GTPase KRAS G12D : a review of patent literature20
PDE1 inhibitors: a review of the recent patent literature (2008-present)20
The intriguing role of USP30 inhibitors as deubiquitinating enzymes from the patent literature since 201320
0.045521020889282